RALEIGH, N.C., April 12, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), reported today that SurgiVision, Inc., a privately held company, and Brainlab AG, announced on April 11 a collaboration aimed at integrating SurgiVision’s ClearPoint® product line with Brainlab’s iMRI product line, with particular focus on local delivery of drugs and other therapeutic agents to precision targets in the brain under magnetic resonance imaging (MRI) guidance. DARA presently owns over 500,000 shares and warrants of SurgiVision.
